Astellas, Minovia partner on mitochondrial cell therapies

By The Science Advisory Board staff writers

July 30, 2021 -- Astellas Pharma and Minovia Therapeutics have signed a strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.

As part of the collaboration, the companies will create allogeneic mitochondrial cell therapy programs. Jointly, the companies will research candidates comprised of cells derived from Astellas' proprietary genetically engineered, induced pluripotent stem cells and modified with Minovia's proprietary mitochondrial augmentation therapy (MAT) technology. The goal is to treat mitochondrial dysfunction through the transfer of healthy mitochondria.

MAT technology involves isolating a patient's own cells, loading them with healthy mitochondria obtained from a healthy donor, and reinfusing the cells back into the patient. Minovia is currently investigating the platform with preclinical research and clinical studies.

Astellas is leveraging its U.S. subsidiaries, the Astellas Institute for Regenerative Medicine and Universal Cells, as part of its efforts to develop allogeneic, off-the-shelf, differentiated cell therapy programs derived from pluripotent stem cells.

The collaboration follows Astellas' recent acquisition of Mitobridge and Nanna Therapeutics and will extend the company's capabilities in mitochondrial biology.

Under the agreement, Minovia will receive an upfront cash payment of $20 million. Further, if Astellas develops and commercializes product candidates for diseases caused by mitochondrial dysfunction, Minovia is eligible to receive up to $420 million per product in future development, regulatory, and commercial milestone payments from Astellas.

Astellas establishes Astellas Gene Therapies to focus efforts
Astellas Pharma announced that it will integrate its wholly owned subsidiary, Audentes Therapeutics, and establish Astellas Gene Therapies within the...
Astellas announces 'golden ticket' winners
Astellas Venture Management, a subsidiary of Astellas Pharma and LabCentral, announced that Axonis Therapeutics and Tenza are the 2020 winners of the...
Astellas, MBC BioLabs call for scientists to enter 'Golden Ticket Competition'
Astellas Venture Management and Mission Bay Capital BioLabs (MBC BioLabs) are collaborating again on the "Golden Ticket Competition," which offers up...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter